$PBLS
Parabilis Medicines, Inc. Common Stock
XNAS•Health Care•Pharmaceutical Preparations
$24.79
▼-7.91%-$2.13
Subscriptions are live. Early access $24.99/mo, or start with 5 free premium days.
Plans & pricingDonateParabilis Medicines, Inc. Common Stock
XNAS•Health Care•Pharmaceutical Preparations
Why is PBLS down today? It is at $24.79 (-7.91%), and our scanner flagged it 130 times on unusual volume this month. See the catalyst behind the move, real-time alerts the moment PBLS spikes, and full due diligence on PBLS — key stats, earnings, dilution and insider activity. Free.
Our scanner flagged $PBLS 130 times in the last 30 days. Create a free account to track $PBLS, build a watchlist, and get instant unusual-volume alerts, with a full day of premium now and 5 more when you verify your email, no card needed.
No card · 5 premium days · join 800+ traders
The top plays and unusual-volume catches our scanner flags, emailed to you. No account needed.
No spam. Unsubscribe anytime. Not investment advice.
Here is the latest on PBLS from our scanner (live price and day move above). A move this size is almost always tied to a specific catalyst. Most of the time that is an earnings report, a guidance update, or a company announcement. If none is shown above, the release may not be in our news feed yet. It will show up here as soon as it is.
Likely catalystClinical / FDA update, from the latest SEC filing. Read it →Across every filing on file, supply equal to 25.8% of the tradeable float is in play - 25.8% has already been sold.
Recent priced share offering — a one-time sale that has already completed (not ongoing)
5,025,000 new shares
Sources: float & market cap via Polygon · short interest via FINRA · borrow & shortability via Alpaca · SSR from Reg SHO 201 · filings & dilution via SEC EDGAR · analysts via Nasdaq.
Auto-generated from public data for research and education. Not investment advice.
| Insider | Action | Shares | % of position | Owns after | Value | Date |
|---|---|---|---|---|---|---|
Ra Capital Management, L.P. Director | Bought (open market) | +47K 0.04% of company | added 0.2% | 29.18M | $1.4M at $29.77 | Jul 22, 26 |
Ra Capital Management, L.P. Director | Bought (open market) | +66K 0.05% of company | added 0.2% | 26.48M | $1.8M at $27.96 | Jul 21, 26 |
Ra Capital Management, L.P. Director | Bought (open market) | +131K 0.1% of company | added 0.5% | 26.42M | $3.6M at $27.13 | Jul 20, 26 |
Sebulsky Alan Director | Bought (open market) | +9K | added 43% | 30K | $236K at $26.00 | Jun 15, 26 |
Sebulsky Alan Director | Bought (open market) | +8K | added 67% | 21K | $233K at $27.67 | Jun 12, 26 |
Flynn James E Beneficial Owner (10%) | Acquired (grant/award) | +1.88M 1.5% of company | n/a | 1.88M | n/a | Jun 11, 26 |
Borisy Alexis Director | Acquired (grant/award) | +105K 0.09% of company | n/a | 105K | n/a | Jun 11, 26 |
Sebulsky Alan Director | Bought (open market) | +13K 0.01% of company | n/a | 13K | $250K at $20.00 | Jun 11, 26 |
Fitzgerald Edward M Director | Acquired (grant/award) | +15K 0.01% of company | n/a | 15K | n/a | Jun 11, 26 |
Ra Capital Management, L.P. Director | Acquired (grant/award) | +7.74M 6.4% of company | n/a | 6.56M | n/a | Jun 11, 26 |
Ra Capital Management, L.P. Director | Bought (open market) | +21.19M 17.4% of company | added 100% | 28.93M | $423.8M at $20.00 | Jun 11, 26 |
Levy Guy Beneficial Owner (10%) | Bought (open market) | +500K 0.4% of company | added 95% | 1.03M | $10.0M at $20.00 | Jun 11, 26 |
Recent Form-4 filings via Nasdaq. Open-market buys are the signal worth watching. Grants and automatic (10b5-1) sells are routine. “% of position” is the share of that insider’s own holding the trade moved. Not investment advice.
Blend of news sentiment, today’s move, and community votes. Not investment advice.
News, unusual-volume alerts, AI-trader trades and community chatter - the whole story, newest first.
The tickers our scanner is lighting up most over the last 48 hours.
Comparable names in pharmaceutical preparations, closest in size first.
Here is the latest on PBLS from our scanner (live price and day move above). A move this size is almost always tied to a specific catalyst. Most of the time that is an earnings report, a guidance update, or a company announcement. If none is shown above, the release may not be in our news feed yet. It will show up here as soon as it is.
PBLS last traded at $24.79, down 7.91% on the day. The price and chart above update live during market hours (4 AM to 8 PM ET).
Parabilis Medicines, Inc. Common Stock (PBLS) is next expected to report earnings on Thursday, November 12, 2026, about 19 days away. Earnings reports often cause large overnight gaps, so many traders manage risk around the date. The date can shift until the company officially confirms it.
The PBLS Live Alerts panel on this page streams real-time unusual volume (RVOL), momentum, halt and 200-EMA alerts from our scanner the moment they fire. Our scanner has flagged PBLS 130 times in the last 30 days.
PBLS (Parabilis Medicines, Inc. Common Stock) trades on XNAS, with a market cap of about $2.98B in the Pharmaceutical Preparations sector.
That depends on your strategy and risk. Day traders look for volume, volatility and a clear trend. Use the live chart, RVOL alerts and 200-EMA context on this page to judge PBLS for yourself. This is not investment advice.
Live data from TheDesperateTrader scanner. Not investment advice.
$PBLS discussion
Sign in to ask a question or join the discussion.